Sunday, November 17, 2019
News

Antibody-based eye drop may treat dry eye disease: Study

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

Washington D.C. | October 13, 2019 11:11:57 PM IST
Researchers found that patients suffering from dry eye can be cured with a new eye drop made from human antibodies.

Researchers at the University of Illinois at Chicago are the first to identify the presence of a specific type of antibody, called anti-citrullinated protein autoantibodies, or ACPAs, in human tear fluid.

They are also the first to demonstrate that patients with dry eye disease experienced reduced signs and symptoms of the condition in response to a new eye drop treatment -- made from human pooled antibodies -- that targets ACPAs.

The findings from their early-stage clinical trial are reported in the journal -- The Ocular Surface.

Dry eye disease is caused by abnormalities in the tear fluid and results in dry areas over the cornea, the transparent outer layer of the eye, which can lead to disabling eye pain and sensitivity to light in severe cases.

"The burden of autoimmune dry eye is much greater than just having an occasional feeling of dryness," said Dr Sandeep Jain, senior author of the study and UIC professor of ophthalmology and visual sciences at the College of Medicine.

"It can severely compromise the quality of life to the point of disability and can compromise a person's vision," added Dr Jain.

In previous research, Jain and his colleagues discovered that strands of DNA extrude from neutrophils, a type of white blood cell, to form webs on the surface of eyes affected by severe dry eye disease and cause inflammation.

In the new study, the researchers identified ACPAs as another cause of eye inflammation that also contributes to the development of these webs, which Jain calls "a vicious cycle of inflammation.

The new eye drops treat dry eye disease by knocking the immune system out of this cycle, at least partially.

The drops are formulated using pooled antibodies -- which are made from immune globulins processed from the donated blood of thousands of individuals, all containing varied types of antibodies -- that counteract the negative effects of ACPAs.

The phase I/II drug trial compared the antibody-based eye drops with eye drops without the antibodies.

"There are currently only two approved drugs to treat dry eye, and they don't work for everyone, especially those with severe disease, so having a new drug that can treat the disease by targeting a different mechanism, in this case, autoimmunity, is very important," Jain said.

The researchers evaluated patients' symptoms through questionnaires and found that people using antibody-based eye drops had a statistically significant and clinically meaningful reduction in corneal damage at eight weeks compared with the control group. (ANI)

 
  LATEST COMMENTS (0)
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
 
MORE HEALTH NEWS
Intermittent fasting may lead to longer,...
UK royals undergo wellness treatment in ...
Eating disorder can hide behind normal b...
Intermittent fasting found to increase l...
Increasing exercise level with age preve...
UK royals undergo wellness treatment in ...
More...
 
INDIA WORLD ASIA
Cong not even called to stake claim to f...
It is our right to file review petition:...
Bihar: Man declared dead in mob lynching...
BJP Parliamentary Executive meeting held...
Pilgrims throng Sabarimala as 2-month se...
Ram Temple construction in Ayodhya to be...
More...    
 
 Top Stories
Opposition raises Abdullahs detenti... 
Mahant commits suicide in Prayagraj... 
Sidharth Malhotra elated with 'Marj... 
Elephant that killed 5 people in Go... 
You are VC of JNU, not Superintende... 
Leaked documents reveal details of ... 
Salman Khan lauds bond with bodygua... 
Virgil Van Dijk withdraws from Neth...